Skip to main content
Scope Fluidics S.A. logo

Scope Fluidics S.A. — Investor Relations & Filings

Ticker · SCP ISIN · PLSCPFL00018 LEI · 259400EUNFX4E2BEHU15 WAR Professional, scientific and technical activities
Open in API
Filings indexed 518 across all filing types
Latest filing 2021-06-10 Declaration of Voting R…
Country PL Poland
Listing WAR SCP

About Scope Fluidics S.A.

https://scopefluidics.com/

Scope Fluidics S.A. is a biotechnology company that develops innovative medical diagnostic solutions based on microfluidic technologies. The company's business model involves incubating projects within special-purpose vehicles (SPVs) with the goal of selling them to global strategic partners. Its primary project, developed by its subsidiary Bacteromic Sp. z o.o., is the BACTEROMIC system. This automated system provides rapid, comprehensive antimicrobial susceptibility testing (AST) to address the challenge of antibiotic resistance. Previously, the company developed the PCR|ONE system for rapid molecular diagnostics through its Curiosity Diagnostics SPV, which was acquired by Bio-Rad in 2022. The company focuses on creating fast, effective, and accessible diagnostic tools to improve healthcare outcomes.

Recent filings

Filing Released Lang Actions
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na NWZ 07.06.2021
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document text is a table detailing the list of shareholders ('Wykaz akcjonariuszy') who held at least 5% of the votes at an Extraordinary General Meeting ('Nadzwyczajnym Walnym Zgromadzeniu') held on June 7, 2021. This content directly relates to the official results of a shareholder vote at a general meeting, listing the resulting voting power distribution. This aligns perfectly with the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document is short and contains the results themselves, not an announcement about the results being published.
2021-06-10 Polish
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Nadzwyczajnym Walnym Zgromadzeniu Spółki, które odbyło się w dniu 7 czerwca 2021 r. - Content (PL)
Major Shareholding Notification Classification · 99% confidence The document text is very short (205 characters) and states that the Management Board ('Zarząd') is attaching a list of shareholders who held at least 5% of the votes at an Extraordinary General Meeting ('Nadzwyczajnym Walnym Zgromadzeniu') held on June 7, 2021. This content directly relates to the results or participants of a shareholder vote, which aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' (DVA). It is not a full report, presentation, or standard regulatory filing, but a specific announcement related to voting outcomes/shareholder structure during a meeting.
2021-06-10 Polish
Rozpoczęcie walidacji systemu BacterOMIC w drugim zewnętrznym laboratorium - Content (PL)
Regulatory Filings Classification · 92% confidence The document text is a short announcement (724 characters) from the Management Board ('Zarząd') of Scope Fluidics S.A. It discusses the progress of a validation system (BacterOMIC) in external laboratories and provides an updated timeline for pre-registration studies, mentioning the impact of Covid-19. This content relates to operational updates and future timelines, which is characteristic of a general regulatory announcement or a report on operational progress, but it is not a full financial report (10-K, IR), an earnings release (ER), or a specific management discussion (MDA). Given its brevity and nature as an update on ongoing operational/testing progress, it fits best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, as it doesn't fit the more specific operational/legal/management categories.
2021-06-08 Polish
Rozpoczęcie certyfikacyjnych testów klinicznych na panel SARS-CoV-2 - Content (PL)
Regulatory Filings Classification · 99% confidence The document text is a formal announcement from the Management Board ('Zarząd') of Scope Fluidics S.A. regarding the commencement of clinical certification tests for their SARS-CoV-2 panel, which are necessary for obtaining European CE-IVD certification and potentially FDA EUA certification. This content relates to product development, regulatory pathways for medical devices, and future regulatory filings. It is not a full financial report (10-K, IR), an earnings release (ER), a dividend notice (DIV), or a management discussion (MDA). Since it details specific regulatory/product progress that will lead to future certification filings, and it is a direct operational update from management concerning product approval status, it best fits the category for general regulatory or operational updates that are not covered by more specific financial or governance codes. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a specific operational/regulatory progress update that isn't explicitly defined elsewhere, although it strongly relates to product approval processes.
2021-06-02 Polish
Otrzymanie przez Bacteromic certyfikatu ISO 13485:2016 - Content (PL)
Regulatory Filings Classification · 100% confidence The document is a short announcement (823 characters) from the Management Board of Scope Fluidics S.A. informing about its subsidiary receiving an ISO 13485:2016 certificate from the Polish Centre for Testing and Certification (PCBC) for its in vitro diagnostic systems. This is a specific operational update regarding quality certification, not a standard financial report (like 10-K, IR, ER) or a management/board change (MANG). It does not fit neatly into the primary categories like AGM, Financing, Dividend, or Legal. Given its nature as a specific, non-financial regulatory/operational update that doesn't match the other specific codes (like DIRS, DIV, CT, etc.), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous official announcements.
2021-06-01 Polish
Decyzja Zarządu o zamiarze wystąpienia do Walnego Zgromadzenia Spółki z wnioskiem o podjęcie uchwały w sprawie dopuszczenia i wprowadzenia akcji Spółki do obrotu na rynku regulowanym GPW - Content ...
Delisting Announcement Classification · 99% confidence The document text, written in Polish, discusses the Management Board's (Zarząd) decision to propose a resolution at the General Meeting (Walne Zgromadzenie) to admit and introduce all existing shares of the Company (Scope Fluidics S.A.) for trading on the regulated market of the Warsaw Stock Exchange (GPW). It explicitly mentions preparing a prospectus and submitting it to the Polish Financial Supervision Authority (Komisja Nadzoru Finansowego). This action directly relates to listing shares on an exchange, which falls under capital structure changes or financing activities. Since the core action is preparing for listing/trading on the exchange, it aligns best with 'Capital/Financing Update' (CAP) or potentially a precursor to a share listing (SHA). Given the focus on admission to trading and preparing a prospectus, CAP is the most appropriate fit as it covers financing activities and capital structure changes related to market access. The document is short and announces an intention/decision, not the final listing itself.
2021-06-01 Polish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.